Search Results for keywords:"pharmaceutical manufacturers"

Search Results: keywords:"pharmaceutical manufacturers"

H. R. 10238 — To authorize the collection of supplemental payments to increase congressional investments in medical research, and for other purposes.
💰
November 21, 2024
Status:Introduced in House
Congress:118
Words:3,758
H.R. 10238, titled the "Medical Innovation Act of 2024," allows the U.S. government to collect additional payments from drug manufacturers to boost funding for medical research. This bill targets "blockbuster" drugs, which are those generating over $1 billion in net sales and developed using...
Simple Explanation
The Medical Innovation Act of 2024 is a plan where the U.S. government wants to collect extra money from companies that make really popular and successful medicines. This money will help make sure scientists have enough funds to continue researching and discovering new medical treatments.
H. R. 10239 — To amend the Federal Food, Drug, and Cosmetic Act to expand drug shortage notification practices to include surges in demand for a drug, and for other purposes.
November 21, 2024
Status:Introduced in House
Congress:118
Words:1,005
The bill H.R. 10239, known as the "End Drug Shortages Act," aims to amend the Federal Food, Drug, and Cosmetic Act to improve how drug shortages are managed in the U.S. It requires manufacturers to notify authorities not only of production interruptions but also when there is...
Simple Explanation
The End Drug Shortages Act wants drug factories to let people know if there’s not only a problem with making enough medicine but also if lots more people suddenly need it. This makes sure there’s enough medicine for everyone and helps doctors, nurses, and patients know what’s happening.
S. 5510 — To amend title XI of the Social Security Act to require pharmaceutical and device manufacturers to publicly disclose covered payments made to patient advocacy organizations.
December 12, 2024
Status:Introduced in Senate
Congress:118
Words:660
The bill S. 5510 is designed to amend the Social Security Act to require pharmaceutical and device manufacturers to disclose payments made to patient advocacy organizations. This would entail that, starting from March 31, 2026, companies must report any direct or indirect...
Simple Explanation
The bill wants companies that make medicine and medical gadgets to tell everyone about the money they give to groups that help sick people. This is to make sure everything is open and honest so people know how these groups are funded.
H. R. 7717 — To amend title XI of the Social Security Act to enhance pharmacy benefit manager transparency requirements.
March 19, 2024
Status:Introduced in House
Congress:118
Words:796
H.R. 7717 aims to increase transparency in how pharmacy benefit managers (PBMs) operate under the Social Security Act. It requires entities providing pharmacy benefits to share detailed financial information with the Secretary of Health and Human Services and relevant health...
Simple Explanation
H.R. 7717 is a rule that wants companies who help people get their medicine to tell everyone more about where their money comes from and goes. This will help people understand how these companies work and make sure they're fair by 2027.

Showing 1 to 4 of 4 results